EGFR T790M/FAK-IN-1 

EGFR T790M/FAK-IN-1 is a dual inhibitor of EGFR^T790M and FAK, with an IC₅₀ of 99.1 nM against EGFR^T790M and an IC₅₀ of 117.7 nM against FAK. EGFR T790M/FAK-IN-1 can be used for research on pancreatic cancer, drug-resistant breast cancer, and drug-resistant lung cancer^[1].

EGFR^T790M/FAK-IN-1 (Compound 9g) (1.25-40 μM; 72 h) inhibits AsPC-1 pancreatic cancer cell proliferation with an IC₅₀ of 1.882 μM^[1].
EGFR^T790M/FAK-IN-1 (Compound 9g) (1.25-40 μM; 72 h) inhibits BxPC-3 pancreatic cancer cell proliferation with an IC₅₀ of 1.947 μM^[1].
EGFR^T790M/FAK-IN-1 (Compound 9g) (1.25-40 μM; 72 h) inhibits Panc-1 pancreatic cancer cell proliferation with an IC₅₀ of 1.787 μM^[1].
EGFR^T790M/FAK-IN-1 (Compound 9g) (1.25-40 μM; 72 h) inhibits Hpde6-c7 normal human pancreatic ductal cell proliferation with an IC₅₀ of 2.066 μM^[1].
EGFR^T790M/FAK-IN-1 (Compound 9g) (1.25-40 μM; 72 h) inhibits MCF-7/adr drug-resistant breast cancer cell proliferation with an IC₅₀ of 0.716 μM^[1].
EGFR^T790M/FAK-IN-1 (Compound 9g) (1.25-40 μM; 72 h) inhibits H1975 drug-resistant lung cancer cell proliferation with an IC₅₀ of 0.513 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

524.02

C₂₆H₃₀ClN₇O₃

2143104-16-7

O=C(NCC)C=1C=CC=CC1NC2=NC(=NC=C2Cl)NC3=CC=C(NC(=O)CN4CCOCC4)C(=C3)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ai M, et al. Design and synthesis of diphenylpyrimidine derivatives (DPPYs) as potential dual EGFR T790M and FAK inhibitors against a diverse range of cancer cell lines. Bioorg Chem. 2020 Jan;94:103408.